- Home
- SEER vs ZNTL Comparison
SEER vs ZNTL Comparison
Compare SEER & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- ZNTL
- Stock Information
- Founded
- SEER 2017
- ZNTL 2014
- Country
- SEER United States
- ZNTL United States
- Employees
- SEER N/A
- ZNTL N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- ZNTL Health Care
- Exchange
- SEER Nasdaq
- ZNTL Nasdaq
- Market Cap
- SEER 113.8M
- ZNTL 118.3M
- IPO Year
- SEER 2020
- ZNTL 2020
- Fundamental
- Price
- SEER $2.25
- ZNTL $1.53
- Analyst Decision
- SEER
- ZNTL Buy
- Analyst Count
- SEER 0
- ZNTL 6
- Target Price
- SEER N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- SEER 96.2K
- ZNTL 751.6K
- Earning Date
- SEER 11-06-2025
- ZNTL 11-06-2025
- Dividend Yield
- SEER N/A
- ZNTL N/A
- EPS Growth
- SEER N/A
- ZNTL N/A
- EPS
- SEER N/A
- ZNTL N/A
- Revenue
- SEER $16,288,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SEER $25.97
- ZNTL N/A
- Revenue Next Year
- SEER $24.00
- ZNTL N/A
- P/E Ratio
- SEER N/A
- ZNTL N/A
- Revenue Growth
- SEER 10.52
- ZNTL N/A
- 52 Week Low
- SEER $1.62
- ZNTL $1.01
- 52 Week High
- SEER $2.63
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- SEER 48.61
- ZNTL 43.89
- Support Level
- SEER $2.15
- ZNTL $1.50
- Resistance Level
- SEER $2.41
- ZNTL $1.82
- Average True Range (ATR)
- SEER 0.09
- ZNTL 0.10
- MACD
- SEER -0.00
- ZNTL -0.01
- Stochastic Oscillator
- SEER 22.22
- ZNTL 7.69
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.